Apply to join the ENABLE-2 consortium
New Open call launched December 20, 2022
ENABLE-2 is accepting molecules with direct acting systemic antibacterial activity and a novel mode of action targeting the ESKAPE pathogens: carbapenem-resistant Enterobacteriaceae, P. aeruginosa, A. baumannii; methicillin-resistant S. aureus; vancomycin-resistant E. faecium. Priority will be given to Gram-negative programmes.
Call closes Sunday January 8, 2023.
The ENABLE-2 platform offers further development of Hits up to a level of advancement where they can successfully graduate to later stage initiatives (e.g., CARB-X, GARDP, REPAIR Impact Fund) or to out-licensing.
Novel modes of action can include action at a novel target, a novel mechanism of action against a known target, or a known mechanism of action against a known target so long as there is demonstrated activity against target-based resistant strains and management of known liabilities is appropriate.
Academics and SMEs within Sweden are eligible to submit a three-page Expression of Interest (EoI) to the ENABLE-2 platform with details of their anti-bacterial programme. SMEs receiving a positive evaluation from the PMC, and after completion of a description of work (DoW) with input from the ENABLE-2 management team may have the opportunity to apply for funding from VINNOVA.
Publicly funded universities from Europe are also eligible to submit a three-page Expression of Interest (EoI) to the ENABLE-2 platform.
PROJECT ENTRY THRESHOLDS
Molecules/series with a novel mode of action targeting in-scope pathogens
- direct acting small molecules and natural products for systemic activity
- potentiation effect possible (eg beta-lactamase inhibitors)
- activity against resistant clinical strains
- single pathogen spectrum possible
Minimum inhibitory concentration (MIC) ≤ 16 μg/mL vs. at least one of the key ENABLE-2 pathogens
- E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, S. aureus, E. faecium
- specific antibacterial activities (activities not due to broad cytotoxicity)
Potential for optimization
- proven chemical structure and preliminary Structure–Activity Relationship
- reasonable route of synthesis (or proven availability if a Natural Product)
- favorable chemical properties allowing iv and/or oral administration
- clear legal/IP situation
Anders Karlén, Coordinator, Professor
Uppsala University (SE)
email@example.com, +46 (0)70-167 9177